FDMT
4D Molecular Therapeutics Inc
NASDAQ: FDMT · HEALTHCARE · BIOTECHNOLOGY
$8.87
+0.68% today
Updated 2026-04-30
Market cap
$479.88M
P/E ratio
—
P/S ratio
5.63x
EPS (TTM)
$-2.42
Dividend yield
—
52W range
$3 – $12
Volume
0.8M
4D Molecular Therapeutics Inc (FDMT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-164.40%
Operating margin
17.40%
ROE
-27.60%
ROA
-17.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $5.79M | $-11.22M | -134.42% | -194.68% | -193.83% |
| 2018 | $14.13M | $-9.55M | -29.95% | -73.60% | -67.59% |
| 2019 | $6.99M | $-49.31M | -454.22% | -726.65% | -705.78% |
| 2020 | $13.61M | $-56.69M | -289.64% | -416.28% | -416.49% |
| 2021 | $18.04M | $-68.30M | 100.00% | -395.46% | -378.63% |
| 2022 | $3.13M | $-101.08M | 100.00% | -3,516.52% | -3,230.30% |
| 2023 | $20.72M | $-100.84M | -368.54% | -544.65% | -486.59% |
| 2024 | $37000.00 | $-160.87M | 100.00% | -507,678.38% | -434,778.38% |
| 2025 | $85.21M | $-140.11M | 91.05% | -187.24% | -164.43% |